coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Clayton Beswick & Openshaw PCN, Manchester (LAD) · Health Inequalities Profile

    PCN U49529 · NHS Greater Manchester Integrated Care Board · 7 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    49,793

    Registered population

    62.8% aged 18–64

    11.9%

    Aged 65+

    ICB 14.9% · England 17.9%

    36.1%

    Ethnic minority (non-White)

    11.3% Asian · England 9.6%

    76.5%

    In IMD quintile 1

    ICB 40.7% · England 21.0%

    ~25,072

    Core20 residents (est.)

    Resident basis; registered basis ~40,513 · see page 3

    7,048

    Hypertension register

    +8.80% in 3 yrs · England +5.60%

    622

    SMI register

    6.6% of Manchester (LAD)'s

    1,388

    COPD register

    Reviews +12.65% in 3 yrs

    Forecast to 2030

    8,489

    Hypertension patients, 2030

    +1,441 on today

    88.8%

    QRISK ≥20% on statins, 2030

    +5.63pp over 3 yrs

    3.1%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    914
    Asthma review gap alongside high youth prescribing.

    With 67.9% of 2,846 asthma patients reviewed, about 910 lack a 12-month review while youth asthma prescribing is 1,832 per 1,000 (England 1,488).

    70.2%
    Pre-school booster and MMR2 trail the target.

    Age-5 4-in-1 booster coverage is 70.2% (England 80.9%), 24.8 pp below the 95.0% target, while age-5 MMR2 is 76.2% (England 82.8%).

    76.1%
    Lipid therapy and COPD reviews exceed England.

    Lipid-lowering therapy in QRISK ≥ 20% reaches 76.1% (England 63.6%; ICB 67.0%), and 12-month COPD reviews reach 80.8% (England 76.4%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Children comprise 25.3% of registered patients while non-White residents reach 36.1%

    Across 7 practices and 49,793 registered patients, Clayton Beswick & Openshaw PCN is younger than benchmarks: 25.3% (12,594 patients) are aged 0-17 (Manchester 21.4%; ICB 21.8%; England 19.6%), while 11.9% (5,926 patients) are aged 65+ (Manchester 9.6%; ICB 14.9%; England 17.9%). Census usual residents (not registered patients) indicate a 36.1% non-White population, led by Black residents at 16.1% (Manchester 11.9%; ICB 4.7%; England 4.2%) and Asian residents at 11.3% (Manchester 20.9%; ICB 13.6%; England 9.6%).

    Age profile

    0–1725.3%
    18–6462.8%
    65+11.9%

    65+: ICB 14.9%, England 17.9%

    Ethnicity

    White63.9%
    Black16.1%
    Asian11.3%
    Mixed4.9%
    Other3.8%

    Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Manchester LA)2,3572,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)80.6%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)53.4%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Manchester LA)1,2811,0219552024/25
    Falls deaths, all ages, per 100,000 (Manchester LA)26.818.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 patients represent 76.5% of registrations, varying by 26.4 pp across practices

    The PCN has an average IMD decile of 2.1, compared with 3.0 in Manchester, 4.5 in the ICB, and 5.5 in England. Across the PCN, 76.5% of registered patients are in the Core20 cohort (Manchester 59.8%, ICB 40.7%, England 21.0%). Practice shares range by 26.4 pp, from 66.3% at Lime Square Medical Centre to 92.7% at Five Oaks Family Practice. Practice Core20 estimates total 40,513 registered patients versus 25,072 resident decile 1+2 estimates. Reconciling these denominator bases is necessary before targeting Core20 outreach.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Five Oaks92.7% · 7,708 patients
    Florence House88.9% · 9,492 patients
    Cornerstone84.7% · 6,373 patients
    Dr Khan's82.4% · 2,395 patients
    Drs Hanif &77.0% · 4,431 patients
    Eastlands73.9% · 4,132 patients
    Lime Square66.3% · 5,982 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    622

    SMI register

    1.21% recorded prevalence

    348

    Learning disability register

    0.68% recorded prevalence

    8

    Care homes, 265 beds

    In the PCN catchment

    8.7%

    Provide unpaid care

    Manchester (LAD), Census 2021

    Recorded severe mental illness prevalence is 1.2% (622 patients) and learning disability is 0.7% (348 patients), alongside 8 catchment care homes with 265 beds. Separate Manchester borough data show 8.7% unpaid care and 55 rough sleepers, which cannot be extrapolated to practice lists.

    Severe mental illness: physical health checks

    SMI prevalence is 1.2% (England 1.0%). Over 2023 to 2025, blood pressure check progress (+2.9 pp) trailed England (+4.4 pp), reaching 84.0% (England 83.4%). BMI checks reached 88.2% (England 82.1%). Individual checks do not establish complete physical review completion.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    7,048

    Hypertension register

    +8.80%

    Register growth, 3 yrs

    Manchester (LAD) +4.49% · England +5.60%

    +2.78pp

    BP control, under 80

    ≤140/90 · +1.33pp aged 80+

    +1,441

    More patients by 2030

    Forecast 8,489 (16.24%)

    Hypertension case-finding and control

    Hypertension prevalence is 13.7% (7,048 patients), above Manchester LAD (10.5%) but below the ICB (14.4%) and England (15.2%). The register grew +8.8% over 2023 to 2025 (England +5.6%). Blood pressure checks reached 89.1% (England 90.0%; ICB 90.3%), while control to target was 69.4% (England 70.3%; ICB 71.4%). For patients aged under 80, control reached 66.8% (England 67.8%; ICB 68.6%), while control at age 80+ was 82.4% (England 81.2%). Observation periods are not confirmed. Trailing ICB and England benchmarks for blood pressure control among patients aged under 80 suggests an opportunity to prioritise clinical titration reviews.

    Lipids and statins

    Lipid therapy in patients with QRISK ≥ 20% reached 76.1%, exceeding Manchester LAD (70.5%), the ICB (67.0%) and England (63.6%), alongside strong coverage in diabetes (80.5% without CVD; 90.4% with CVD). Exceeding national lipid therapy benchmarks across high-risk groups means the PCN should focus on sustaining routine initiation and monitoring.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202694,498£1.80£1.94£1.86£170,096
    Cardiovascular (all), 2025128,635£2.41£3.15£3.33£310,010

    For lipid-regulating drugs in 2026, the PCN prescribed 94,498 items at £1.80 per item (spend £170,096), below England (£1.86), the ICB (£1.94) and Manchester LAD (£2.21). The PCN spent £5,670 less than at England's unit cost. Lower unit costs than England indicate an opportunity to confirm that lipid-regulating prescribing aligns with clinical appropriateness across target patient cohorts.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +4.86%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +1.25%

    Asthma prevalence, PCN 3-yr % change

    COPD prevalence is 2.7% (1,388 patients; England 1.9%), with 80.8% reviewed within 12 months (England 76.4%; +12.7% over 2023 to 2025 vs England +2.8%). Asthma prevalence is 6.0% (2,846 patients; England 6.6%). While 67.9% received an annual review (England 65.7%), about 910 patients remain unreviewed. Furthermore, young-person asthma prescribing is high at 1,832 items per 1,000 aged 5-19 (England 1,488), while second-hand smoke recording trails at 75.8% (England 78.8%). High paediatric prescribing alongside unreviewed patients highlights an operational need to proactively target routine reviews.

    Cancer register and children's immunisation

    Cancer prevalence is 2.5% (1,269 patients), below England (3.8%). In childhood immunisations, Q1 2025/26 COVER data shows uptake below the 95.0% target across milestones: 6-in-1 at 12 months is 88.9% (England 91.0%), and MMR1 at 24 months is 84.1% (England 88.3%). By age 5, MMR2 reaches 76.2% (11.9 pp below MMR1 at 88.1%) and the 4-in-1 booster reaches 70.2% (England 80.9%).

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months88.9%

    England 91.0%

    6-in-1 complete primary course at 24 months89.7%

    England 92.2%

    MMR dose 1 at 24 months84.1%

    England 88.3%

    MMR dose 2 at age 576.2%

    England 82.8%

    4-in-1 pre-school booster at age 570.2%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Greater Manchester ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,270

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Greater Manchester ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%15%2,193
    Prostate61.7%53.2%14%1,788
    Breast82.5%85.4%19%1,758
    Bowel46.3%47.0%19%1,427
    Skin cancer84.5%87.8%27%580

    In 2022, 55.6% of cancers with a known stage (6,491 of 11,679) across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (England 55.3%), below the 75.0% national ambition by 2028 by 19.4 pp. Known stage was recorded for 70.8% of registered cancers (11,679 of 16,492), needing about 2,270 extra early-stage cases to reach 75.0%. PCN cervical screening is 63.8% (England 66.8%), spanning 58.5% at Cornerstone Family Practice and 59.5% at Florence House Medical Practice to 69.4% at Five Oaks Family Practice; breast screening is 60.9% (England 69.9%). System staging data cannot establish PCN performance.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    At Manchester University NHS Foundation Trust in Jul 2026 (provisional), 72.8% of cancer pathways met the 62-day referral to treatment standard, below the 85.0% standard by 12.2 pp, compared with Northern Care Alliance NHS Foundation Trust at 78.6%, Tameside and Glossop Integrated Care NHS Foundation Trust at 76.8%, the ICB at 75.7%, and England at 71.2%. On the 28-day faster diagnosis standard, Manchester University NHS Foundation Trust reached 80.1% against the 75.0% standard (Tameside and Glossop 82.5%, ICB 79.5%, England 79.3%, Northern Care Alliance 75.2%). Provider waits describe system capacity, not PCN referral quality.

    Pathways within standard (%)ManchesterTameside and Glossop Integrated CareNorthern Care AllianceGreater Manchester ICBEngland
    28-day faster diagnosis (75%)80.0682.4875.2079.5379.32
    31-day treatment (96%)92.5496.2594.5496.4992.50
    62-day referral to treatment (85%)72.8576.7778.6575.7371.16
    Diagnostic waits over 6 weeks (%)ManchesterTameside and Glossop Integrated CareNorthern Care AllianceEngland
    MRI11.680.005.0921.40
    CT14.660.184.109.92
    Echocardiography4.910.0031.4828.48
    Colonoscopy4.511.5140.0430.83
    Gastroscopy29.355.4536.4829.02
    All 15 DM01 tests8.980.8015.7123.14
    Community services activityManchester residentsGreater Manchester ICB
    Care contacts96,995573,310
    Referrals20,27094,470
    Patients with a contact31,040183,535

    Community services (residents of Manchester), Jun 2026 (provisional). In Jun 2026 (provisional), community service contacts for Manchester borough residents totalled 96,995, with 42,015 contacts involving adults aged 65+, representing 43.3% of all activity. These figures reflect local authority resident contacts rather than PCN-level or registered-patient service activity, so community caseloads cannot be attributed directly to individual practices.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice variation and patient experience

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Dr Khan's Practice9782.486.6%74.3%86.7%
    Eastlands10773.974.2%80.5%76.6%
    Five Oaks12792.761.2%67.8%76.6%
    Drs Hanif &7977.059.3%73.5%70.7%
    Cornerstone10784.745.9%83.9%70.5%
    Florence House9388.961.5%65.7%69.4%
    Lime Square10066.350.6%70.6%66.5%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNManchester (LAD)AssetPCNManchester (LAD)
    Care homes (catchment)8 (265 beds)n/aSchools (catchment)57n/a
    Children's centres634Places of worship25289
    Libraries216Homelessness support (VCS)n/a1
    Primary schools (LA maintained)1168Primary academies650
    Special schoolsn/a3

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma review recall

    Across 2,846 asthma patients, 67.9% had a review in 12 months (England 65.7%; ICB 66.2%; Manchester 67.0%), leaving about 910 unreviewed. For discussion: practices could run a single-template asthma recall offering after-school slots and pairing inhaler prescribing checks with second-hand smoke recording. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Pre-school booster and MMR2 recall

    In Q1 2025/26 (cohort 151), age-5 MMR2 is 76.2% (below the 95.0% target by 18.8 pp; England 82.8%) and 4-in-1 booster is 70.2% (below by 24.8 pp; England 80.9%). Moderate effort to run.

    Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.

    Policy anchor: 10 Year Health Plan, shift from sickness to prevention.

    Option 3

    Telephony and front-door access review

    In the Jan-Apr 2026 survey, easy phone contact spans 40.8 pp from 45.9% at Cornerstone Family Practice to 86.6% at Dr Khan's Practice (England 56.9%). Low cost, quick to run.

    Evidence base: conditions and pathways with an established England-wide differential for this group: Hypertension and stroke (higher prevalence, younger and more severe stroke); Type 2 diabetes (higher prevalence); Chronic kidney disease and kidney failure (higher progression to dialysis); Sickle cell disease and trait; Maternal and perinatal mortality (markedly higher); Prostate cancer (about double the lifetime risk); and others. Read this population count as the denominator for those pathways, and expect local rates to differ from the all-ethnicity benchmark in that direction.

    Policy anchor: Health and Wellbeing Boards must develop neighbourhood health plans for 2027/28 during 2026/27; Core20 defined as the most deprived 20% by IMD.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Diverse resident access review (p2)Black / African / Caribbean / Black BritishNeighbourhood health framework · Core20PLUS5 approachPCN
    Two-track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI health check workflows (p4)Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Blood pressure titration recall audit (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Preschool immunisation call recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening recall audit (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Telephony and triage review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Structured asthma review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 PopulationCore20PLUS5 respiratoryPCN
    Option 2 · Pre-school booster and MMR2 recall (p12)MMR dose 2 coverage at age 5 · MMR dose 1 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Option 3 · Telephony and front-door access review (p12)Black / African / Caribbean / Black British · GPPS easy to contact the practice by phone · GPPS survey response rate10YHP, hospital to communityPCN & Practice
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15